Santarem

This research aims to evaluate whether MM09, a sublingual immunotherapy, can help patients aged 12 to 65 with moderate-to-severe allergic rhinitis or rhinoconjunctivitis caused by house dust mites, with or without mild to moderate asthma. The trial is a phase III, randomized, double-blind, placebo-controlled study designed to assess if MM09 reduces symptoms and the need for rescue medications, while also monitoring safety. Participants will receive either the active MM09 sublingual spray or a placebo solution without the active ingredient. The treatment is given daily over 12 months. The study carefully compares the effects of MM09 against placebo to understand its impact on allergic rhinitisrhinoconjunctivitis and asthma symptoms. During the study, participants will record symptoms and medication use via a smartphone app. Researchers will measure combined symptom and medication scores, as well as separate scores for rhinitis, rhinoconjunctivitis, and asthma symptoms and medication intake during the last four weeks of treatment. Safety and any medical problems from inhaling MM09 will be closely monitored throughout the trial, which lasts up to 12 months.

Scientific research has shown that staying active during pregnancy can help prevent and manage complications like gestational diabetes, hypertension, obesity, and improve overall fitness, mental health, and postpartum recovery. However, many pregnant and postpartum women lack proper guidance on exercising safely, and inactivity remains common. This research evaluates the benefits of a supervised prenatal exercise program delivered either in person or online, aiming to improve maternal physical activity, fitness, and healthy lifestyle behaviors. The study offers a 12-week multicomponent exercise program, including aerobic, coordination, strength, postural, stretching, and pelvic floor exercises. Participants attend two 60-minute sessions weekly, supervised by qualified exercise physiologists. Women join either an in-person group at healthcare, university, or fitness centers or an online group exercising at home or outdoors. The program follows international guidelines and includes access to additional free resources like the Active Pregnancy Guide and YouTube workouts. Participants complete validated questionnaires and fitness tests before and after the 12-week intervention to assess physical activity, fitness, sleep, diet, stress, and other health factors. Researchers will compare the effects of in-person versus online exercise on these outcomes and gather participant feedback on satisfaction and resource use. All participation and resources are free, and the study aims to inform future exercise recommendations and public health strategies for pregnant women.

Researchers are evaluating the long-term performance and reliability of Medtronics market-released cardiac rhythm therapy products, including leads and devices used for pacing, sensing, or defibrillation. This observational study aims to analyze how well these cardiac devices function over time by measuring survival probabilities and tracking device-related complications. The study applies to patients with conditions such as arrhythmia, bradycardia, heart failure, and sinus tachycardia. The study includes all Medtronic market-released cardiac leads and implantable devices such as pacemakers IPG, implantable cardioverter defibrillators ICD, and cardiac resynchronization therapy CRT devices. Participants either have a new implant or are within 30 days post-implantation. Data from prior qualifying Medtronic studies with complete follow-up may also be included. The study continuously monitors these products from the time of implant until the lead is no longer in use due to patient exit, death, or device deactivation. Participants provide consent for data access and use, and their health information is tracked over the long term. Researchers evaluate lead-related complications and product survival throughout the study period, which began in 1983 and is ongoing until 2040. The study does not involve additional treatments but collects follow-up data to assess device performance and safety over time.

Researchers are gathering ongoing information on the safety and performance of Medtronic products that are already available on the market. This registry study aims to support patients, hospitals, clinicians, regulators, payers, and the medical industry by simplifying the process of monitoring these products and providing up-to-date performance data. The study involves collecting data on patients who have received or are planned to receive Medtronic medical devices or therapies. Enrollment includes both prospective and retrospective participants within a specific time frame related to their therapy start. There are no specific interventions assigned, as this is an observational registry. Participants provide written consent and are followed periodically, typically every 6 to 12 months depending on the therapy, to assess the safety and effectiveness of their Medtronic product. Researchers collect information from medical records and follow-up visits to monitor outcomes over time. Participants may be followed for many years, with the study currently planned through January 2040.